Immenstaad, December 01, 2020 – ACTICO, a leading international provider of software for intelligent automation and digital decisioning, today announced that CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, successfully implemented the ACTICO platform to accelerate and improve its diagnostic data curation workflow. As a result, rare disease patients will benefit from faster and more accurate diagnoses.
CENTOGENE is committed to reducing patient’s suffering by accelerating and improving the accuracy of rare disease diagnosis. To that end, the Rostock-founded company has developed a unique genetic information database, CentoMD®. CentoMD® 5.8 currently contains over 430,000 analyzed cases as of August 2020 and is a powerful tool in making the rare disease diagnostic process easier, faster and more precise.
“We have a range of standard operating procedures that our medical professionals complete for data curation, and we were exploring the opportunities that artificial intelligence automation solutions could offer,” said Prof. Dr. Carsten Ullrich, Director of Artificial Intelligence at CENTOGENE.
Hans Jürgen Rieder, CEO at ACTICO added, “We are delighted to have enabled CENTOGENE to automate its data curation workflow using the ACTICO decision management system. We worked closely with our implementation partner S&D to ensure a rapid and smooth deployment, and we are very proud of the results.”
Dr. Martin Werber, Senior Technical Project Manager for AI at CENTOGENE, added, “We are now able to batch the processing of thousands of patient samples with this fully integrated solution and save up to one month of manual work for every release of a new version of CentoMD®. For patients, this represents a huge breakthrough. The time previously spent looking at cases of lower complexity can now be spent examining more difficult ones – meaning patients directly benefit.”
CENTOGENE joins hundreds of other businesses around the world that are using ACTICO’s decision management system to leverage the power of AI in automating complex and dynamic decision workflows intelligently.
More information about this success story.
CENTOGENE engages in diagnosis and research around rare diseases transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Our goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our extensive rare disease knowledge, including epidemiological and clinical data, as well as innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with over 3.6 billion weighted data points from approximately 570,000 patients representing over 120 different countries as of August 31, 2020.
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of August 31, 2020, the Company collaborated with over 40 pharmaceutical partners covering over 45 different rare diseases.
ACTICO is a leading international provider of software for intelligent automation and digital decisioning. Its scalable software combines rule-based technology and machine learning in a unique way and is totally audit-proof. It allows companies of all sizes to process huge amounts of data and make and automate AI-supported and rule-based decisions in real time. Through intelligent automation, ACTICO increases the business value of its customers by improving their operational decisions.
Today, its customers include leading companies in 25+ countries ranging from small/mid-size to Fortune 500 companies and has offices in Chicago and Singapore. Its head office is located in Immenstaad, Germany.